South Korea will allow the use of Gilead Sciences' remdesivir to treat COVID-19 patients if clinical tests prove the therapy to be safe and effective, as reported in The Korea Herald.
"In case of contingencies, we will try to give it emergency use authorization and allow its domestic use," said deputy director Kwon Jun-wook of the Korea Centers for Disease Control and Prevention.
Study results recently released by the US National Institute of Allergy and Infectious Diseases showed that hospitalized patients with COVID-19 who received the drug recovered faster than those who received placebo.
Gilead is working with three hospitals in South Korea to clinically test the therapy.
To read more NewsPoints articles, click here.